Literature DB >> 23212094

Blood plasma metabolites and the risk of developing lung cancer in Russia.

Petr G Lokhov1, Oxana P Trifonova, Dmitry L Maslov, Alexander I Archakov.   

Abstract

Lung cancer is one of the most common types of cancer in men, and is a leading cause of cancer-related deaths. Therefore, the identification of specific markers associated with a risk of lung cancer development, particularly metabolites that are more easily assayed, would be very valuable. To this end, а comparative metabolomics study of blood plasma samples collected from patients with lung cancer (n=100) and controls (n=100) recruited in Moscow was carried out. After the extraction of blood plasma proteins with methanol, the remaining plasma metabolite fractions were analyzed directly using mass spectrometry. Hundreds of cancer-associated metabolites were detected, and at least 70 metabolite ions with odds ratio values of 10-288 were found to be associated with the presence of cancer. Although these metabolites were present at higher levels in cancer patients, particularly in the early stages of disease, they did not correlate positively with cancer progression. On the basis of these findings, this metabolomics study of blood plasma samples from cancer patients shows that numerous cancer-associated metabolites were present in the studied population, and these could be used as factors for calculating the risk of lung cancer development in addition to currently used risk factors.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23212094     DOI: 10.1097/CEJ.0b013e32835b3898

Source DB:  PubMed          Journal:  Eur J Cancer Prev        ISSN: 0959-8278            Impact factor:   2.497


  13 in total

1.  Mass spectrometric signatures of the blood plasma metabolome for disease diagnostics.

Authors:  Petr G Lokhov; Elena E Balashova; Anna A Voskresenskaya; Oxana P Trifonova; Dmitry L Maslov; Alexander I Archakov
Journal:  Biomed Rep       Date:  2015-11-24

Review 2.  Postgenomics diagnostics: metabolomics approaches to human blood profiling.

Authors:  Oxana Trifonova; Petr Lokhov; Alexander Archakov
Journal:  OMICS       Date:  2013-09-17

3.  Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma.

Authors:  William R Wikoff; Dmitry Grapov; Johannes F Fahrmann; Brian DeFelice; William N Rom; Harvey I Pass; Kyoungmi Kim; UyenThao Nguyen; Sandra L Taylor; David R Gandara; Karen Kelly; Oliver Fiehn; Suzanne Miyamoto
Journal:  Cancer Prev Res (Phila)       Date:  2015-02-05

Review 4.  Metabolomics Community in Russia: History of Development, Key Participants, and Results.

Authors:  Elena E Balashova; Dmitry L Maslov; Oxana P Trifonova
Journal:  BioTech (Basel)       Date:  2020-10-25

Review 5.  Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma.

Authors:  Johannes F Fahrmann; Dmitry D Grapov; Kwanjeera Wanichthanarak; Brian C DeFelice; Michelle R Salemi; William N Rom; David R Gandara; Brett S Phinney; Oliver Fiehn; Harvey Pass; Suzanne Miyamoto
Journal:  Carcinogenesis       Date:  2017-01-03       Impact factor: 4.944

6.  Diagnosis of Parkinson's Disease by A Metabolomics-Based Laboratory-Developed Test (LDT).

Authors:  Petr G Lokhov; Oxana P Trifonova; Dmitry L Maslov; Steven Lichtenberg; Elena E Balashova
Journal:  Diagnostics (Basel)       Date:  2020-05-21

7.  Diagnosing impaired glucose tolerance using direct infusion mass spectrometry of blood plasma.

Authors:  Petr G Lokhov; Oxana P Trifonova; Dmitry L Maslov; Elena E Balashova; Alexander I Archakov; Ekaterina A Shestakova; Marina V Shestakova; Ivan I Dedov
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

8.  Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment.

Authors:  Desirée Hao; M Omair Sarfaraz; Farshad Farshidfar; D Gwyn Bebb; Camelia Y Lee; Cynthia M Card; Marilyn David; Aalim M Weljie
Journal:  Metabolomics       Date:  2016-02-27       Impact factor: 4.290

Review 9.  Parkinson's Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization.

Authors:  Oxana P Trifonova; Dmitri L Maslov; Elena E Balashova; Guzel R Urazgildeeva; Denis A Abaimov; Ekaterina Yu Fedotova; Vsevolod V Poleschuk; Sergey N Illarioshkin; Petr G Lokhov
Journal:  Diagnostics (Basel)       Date:  2020-05-25

Review 10.  A Metabolomics Approach to Pharmacotherapy Personalization.

Authors:  Elena E Balashova; Dmitry L Maslov; Petr G Lokhov
Journal:  J Pers Med       Date:  2018-09-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.